ArticlePloS one2020
Acute kidney disease stage predicts outcome of patients on extracorporeal membrane oxygenation support.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Renal replacement therapy in patients under extracorporeal membrane oxygenation: a narrative review.Critical care (London, England) · 2026Review
- The burden of acute kidney disease: an epidemiological review and importance of follow-up care.Clinical kidney journal · 2025Review
- Predicting In-Hospital Mortality in Patients with End-Stage Renal Disease Receiving Extracorporeal Membrane Oxygenation Therapy.Cardiorenal medicine · 2025Article
- Incidence, risk factors, and outcomes of the transition of HIPEC-induced acute kidney injury to acute kidney disease: a retrospective study.Renal failure · 2024Article
- Recent Update on Acute Kidney Injury-to-Chronic Kidney Disease Transition.Yonsei medical journal · 2024Review
- Recovery Dynamics and Prognosis After Dialysis for Acute Kidney Injury.JAMA network open · 2024Article
- Outcomes associated with acute kidney disease: A systematic review and meta-analysis.EClinicalMedicine · 2023Article
- Risk factors and 180-day mortality of acute kidney disease in critically ill patients: A multi-institutional study.Frontiers in medicine · 2023Article
- Severe acute kidney disease is associated with worse kidney outcome among acute kidney injury patients.Scientific reports · 2022Article
- Neutrophil-lymphoycyte-ratio, platelet-lymphocyte-ratio and procalcitonin for early assessment of prognosis in patients undergoing VA-ECMO.Scientific reports · 2022Article
- Update on prognosis driven classification of pediatric AKI.Frontiers in pediatrics · 2022Review
- Article
- Correlation Between Higher Cumulative Dose of Cisplatin for Concurrent Chemoradiation and Acute Kidney Disease Incidence Among Nasopharyngeal Carcinoma Patients: A Comparative Study.International journal of general medicine · 2021Article
- Application of Machine Learning to Predict Acute Kidney Disease in Patients With Sepsis Associated Acute Kidney Injury.Frontiers in medicine · 2021Article
- Acute Kidney Injury and Kidney Damage in COVID-19 Patients.Journal of Korean medical science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe mortality rate of patients on extracorporeal membrane oxygenation (ECMO), especially those patients that develop acute kidney injury (AKI) is high. Acute kidney disease (AKD) is a term used to describe the continuum from AKI to chronic kidney disease. However, the role of AKD in predicting the prognosis of patients on ECMO support is unclear.
methodsA total of 168 patients who received ECMO support and survived for more than 7 days at a single hospital from 2003 to 2008 were enrolled for this study and followed up for 10 years or till mortality. Kaplan-Meier analysis and Cox proportional hazards model were used to determine the prognostic factors associated with survival.
resultsThe median survival times of patients with stage 0, stage 1, stage 2 and stage 3 AKD were ≥ 10 years, 43.9 months, 1 month, and half a month, respectively. There were statistically significant differences in cumulative survival rate between patients with stage 3 AKD and those with stage 0, 1, and 2 AKD (Cox-Mantel log rank test, p<0.001, p<0.001, p = 0.023), and between patients with stage 0 AKD and those with stage 1 and 2 AKD (Cox-Mantel log rank test, p = 0.012, p<0.001). Cox regression analysis revealed that AKD stage (hazard ratio [HR]: 2.576, 95% confidential interval [CI]: 1.268-5.234, p = 0.009 for stage 1; HR: 2.349; 95% CI: 1.101-5.512, p = 0.029 for stage 2; HR: 5.252; 95% CI: 2.715-10.163, p<0.001 for stage 3) was significant independent predictor of survival.
conclusionAKD stage is an independent predictor of survival in patients on ECMO support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.